Pelonomi Hospital Doctors FORUM

Pelonomi Hospital Doctors FORUM PELONOMI TERTIARY HOSPITAL - HEIDEDAL, BLOEMFONTEIN, FREE STATE, SOUTH AFRICA

27/03/2016

Using diet to reverse type 2 and remain diabetes-free

FOR IMMEDIATE RELEASE26 January 2016SAMA Calls on the Minister to take action regarding the HPCSAThe South African Medic...
26/01/2016

FOR IMMEDIATE RELEASE
26 January 2016

SAMA Calls on the Minister to take action regarding the HPCSA
The South African Medical Association, SAMA, notes with extreme concern the reported intransigence of the Health Professions Council (HPCSA) in implementing the recommendations of the Ministerial Task Team. The Ministerial Advisory committee reported to the Minister in late 2015 the need to radically reform the structure. Failure to initiate this process demonstrates extreme arrogance of HPCSA management. Inter alia, the report called for the termination of the employment of several officials. The failure of these officials to resign demonstrates breath-taking arrogance if not a lack of honour to do the right thing considering the damning details contained in the report. SAMA calls on the President of Council, Dr Kgosi Letlape, as a fellow doctor to demonstrate the requisite ethical leadership required and transform the HPCSA in line with the recommendations of the report.

The Health Minister has statutory oversight of the HPCSA and is fully entitled to have commissioned the task team review. The team and the report has locus standi.

If there is a failure of the HPCSA to implement the report recommendations, SAMA calls on the Minister to exercise his statutory power and to suspend the entire structure and appoint an interim management team to oversee the process.

END

About SAMA
The South African Medical Association (SAMA) is a non-statutory, professional association for public and private sector medical practitioners. Registered as an independent, non-profit Section 21 company, SAMA acts as a trade union for its public sector members and as a champion for doctors and patients.

Contact:
Head of PR & Communications
Dr Simonia Magadie

Spokesperson
Chairperson: SAMA
Dr Mzukisi Grootboom

Kind regards

SAMA Corporate Communication
[email protected]
Tel: 012 481 2000/2164
Fax: 012 481 2100
http://www.samedical.org/
EMAIL CONFIDENTIALITY NOTICE AND DISCLAIMER
The contents of this email and its attachments (collectively referred to as this email) are CONFIDENTIAL and intended for the named recipient/s ONLY. This includes those persons sent copies. Unless you are the intended recipient, you may not use, copy or disclose this emailif you have received this email message in error, kindly advise the sender by email, and delete the message. Any unauthorised copying, disclosure, adaption, distribution, publication and/or use of, or any other unauthorised action taken based on this email is strictly prohibited and may be unlawful and an infringement of copyright. The South African Medical Association NPC (SAMA) accepts no liability for the content of this email, or for the consequences of any actions taken on the basis of the information provided, unless that information is subsequently confirmed in writing by a duly n authorised representative of SAMA. SAMA reserves the right to check, intercept and block emails, or take any other action according to SAMAs email protocols and policies. Emails may be logged for archival purposes and may be reviewed by parties at the Company other than those named in the message header. The e-mail address of the sender may not be used, copied, sold, disclosed or incorporated into any database or mailing list for spamming and/or other marketing purposes without the prior consent of SAMA. Email transmission cannot be guaranteed to be secure or error-free, as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses or other malicious code. SAMA, therefore, does not accept any liability or responsibility whatsoever for any errors or omissions in the contents of this message which arise as a result of email transmission. If verification is required, please request a hard-copy version. Any views or opinions presented in this email are solely those of the author and do not necessarily reflect the views and opinions of SAMA or its subsidiaries. SAMA employees are not authorised to conclude binding agreements on behalf of SAMA by email and nothing contained in this email shall be construed as a legally binding agreement or an offer to contract. This e-mail disclaimer is enforceable and binding on the recipient in terms of sections 11(1) to 11(3) of the Electronic Communications and Transactions Act 25 of 2002, as amended.

Cardiac MRI – Revolutionizing The Management Of Cardiovascular DiseaseCardiovascular disease is the leading cause of dea...
18/01/2016

Cardiac MRI – Revolutionizing The Management Of Cardiovascular Disease
Cardiovascular disease is the leading cause of death around the world, and the Middle East is no exception – according to the World Health Organization (WHO), the Middle East has one of the highest rates of cardiovascular disease-related mortality in the world. The prevalence of smoking, the high rates of obesity and diabetes, and low rates of physical activity in the Arab world are all to blame.

Although primary prevention of cardiovascular disease, tackling risk factors is always an important goal, timely and accurate diagnosis of heart disease remains an important challenge that is integral to improving disease outcomes. In this regard, new imaging technologies, including cardiac magnetic resonance imaging (MRI), are changing the diagnosis landscape. By allowing non-invasive visualization of the structure and function of the heart as a whole, these new technologies facilitate diagnosis as well as detection of early disease, with the aim to begin treatment and prevent further damage.

Imaging modalities have significantly evolved over the years and now encompass, in addition to the traditional ultrasound and nuclear techniques, special X ray called computed tomography and cardiac MRI. Most of these techniques are available to any facility that takes care of patients with cardiovascular disease and along with appropriately trained staff, have the potential to revolutionize diagnosis and treatment. As such, we need to ensure that clinicians and patients take advantage of this potential and become more familiar with their uses. Will focus today on cardiac MRI.

What is cardiac MRI?

Cardiac MRI has emerged as a key non-invasive imaging approach that has proven to be useful both for diagnosis as well as prognosis for a wide range of cardiovascular diseases. Like other MRI applications, cardiac MRI uses radiofrequency waves, a powerful magnet (around 30,000–60,000 times the strength of the earth's magnetic field) and a computer to create a detailed two-dimensional or three-dimensional picture of the heart. This means that it can be used for real-time imaging of the heart, heart valves and the aorta, as well as the flow of blood through these tissues, and also offers an assessment of the properties of the heart muscle itself.

There are different cardiac MRI techniques that together can offer a more comprehensive assessment of the heart. For example, cardiac MRI can involve the use of a dye (to measure, for instance, the extent of heart damage) or can acquire images of the heart during different stages of the cardiac cycle over several heart beats.

From a clinical perspective, this offers us the ability to visualize and quantify where damage has taken place in patients who have suffered a heart attack, but also to identify areas of the heart that have reduced blood flow owing to blockages or narrowing of the arteries. Other cardiovascular diseases, including valvular heart disease, congenital heart disease, and their effects on the heart function and remodelling can also be imaged.

Beyond diagnosis, cardiac MRI can be used as a prognostic tool, offering useful insights on the effectiveness of a particular treatment, which could be invaluable in the context of clinical trials. Indeed, it is now arguably the gold standard for assessing new interventions for myocardial infarction3.

Benefits over other diagnostic tools

This ability to obtain a more complete picture of the heart, its structure, physiology and function is the key benefit of cardiac MRI over more traditional diagnostic tools such as an electrocardiogram (ECG) or nuclear imaging. Specifically, an ECG records the electrical impulses that are produced by the heart to make the heart muscle contract. Although this is still clinically useful in diagnosing rhythm abnormalities and whether an acute injury of the heart is occurring (acute heart attack or myocardial infarction), among others, such information is greatly limited when compared with the more complete picture offered by cardiac MRI.

Other imaging techniques, including cardiac computed tomography (CT) and ultrasound, also offer invaluable insights that help in the early diagnosis of disease. Indeed, these methodologies complement each other for diagnosis and treatment, and more than one technique will frequently be used to get a better picture of the condition. But in terms of safety, cardiac MRI offers the advantage over CT of not using radiation to generate the image of the heart.

It is, however, important to note here that, like with other MRI applications, cardiac MRI uses a magnetic field, which may be contraindicated in some patients, for example those with older pacemakers. This further emphasizes the importance of selecting an imaging approach based on the patient’s specific circumstances.

Uses of cardiac MRI

It is clear that cardiac MRI has the potential to inform the diagnosis and treatment of a range of cardiovascular conditions. Below is a list of current applications of cardiac MRI to help guide clinicians during the decision-making process. Of course the applications are not limited to the below, and new uses, including T1 mapping and coronary MRI, are also emerging.

Myocardial viability.

Being able to distinguish between viable and dead tissue is a key requirement when evaluating patients who have suffered a heart attack or show cardiac dysfunction. Cardiac MRI is a highly accurate method for assessing and quantifying the presence of scar tissue in the heart. In this context, cardiac MRI is also referred to as viability imaging as it is the only technique that can image and quantify a scar in the heart; it is now the standard approach to measure heart damage, be it secondary to an infarct or from other conditions such as heart inflammation or infection (myocarditis, cardiomyopathy, sarcoid disease). Other characteristics of the infarct, including oedema and haemorrhage in the myocardium, can also be assessed through cardiac MRI.

Ischaemia.

Cardiac MRI allows the visualization of blood flow to the heart (perfusion) and can therefore be an important diagnostic tool for blood flow restriction, or ischaemia particularly during stress testing. Simple visual evaluation of ischaemia is very common in clinical practice with nuclear techniques or echocardiography, but cardiac MRI also offers the ability to quantify the extent of ischaemia3 along with pre-existing scar and total heart function in the same setting.

Valvular disease.

Although echocardiography remains the first-line method of assessing the morphology of heart valves and any related abnormalities that could affect heart size and function, cardiac MRI has become an essential tool in evaluating valvular diseases. Cardiac MRI can be used to identify narrowing of the heart valves as well as leakage of blood back into the heart owing to improper closing of the heart valves (regurgitation) such as aortic regurgitation and mitral regurgitation. Importantly, it is the most accurate modality in quantitating the amount of regurgitation. It is also ideal in situations where the aortic valve is also associated with diseases of the aorta such as a congenitally malformed aortic valve.

Pericardial disease.

Unlike other fields in cardiology, pericardial disease (that is, disease affecting the sac tissue surrounding the heart), has received little interest, and diagnosis is complicated by the fact that pericardial disease can mimic other cardiac or lung diseases. In this regard, imaging approaches, and in particular cardiac MRI, offer invaluable insights on pericardial morphology and effects on cardiac function, and especially the ability to integrate these two aspects in one single examination. Cardiac MRI is increasingly becoming the gold standard non-invasive technique for assessing pericardial disease, including pericarditis (inflammation of the pericardium), pericardial effusion (an increased amount of pericardial fluid) and pericardial constriction (an abnormal thickening of the pericardium).

Congenital heart disease. Imaging is essential for the diagnosis of congenital heart disease, and cardiac MRI now has an integral role, facilitating early diagnosis and treatment. Although echocardiography is the first-line imaging approach used for paediatric patients, cardiac MRI is indicated for patients for whom echocardiography data have been insufficient to facilitate decision-making, particularly complex congenital heart disease.

Non-ischaemic cardiomyopathy.

Cardiac MRI offers invaluable insights on the cause, progression, treatment response and prognosis of non-ischaemic cardiomyopathies, such as sarcoidosis, hypertrophic cardiomyopathy, idiopathic dilated cardiomyopathy or that secondary to iron overload, and infiltrative disease like amyloidosis.

New imaging technologies have really expanded our ability to visualize the heart without having to use invasive procedures such as heart catheterization. Cardiac MRI in particular has shown great promise in the early and accurate diagnosis of a range of heart conditions and is rapidly becoming the gold standard. We now need to ensure that clinicians (and patients) are familiar with its uses to promote its wider clinical acceptance and, ultimately, improve clinical outcomes for patients.

Total Radiology Magazine

18/01/2016

Increasing bowel cancer testing rates through a general practitioner-organised health care package would reduce incidence and prove cost-effective

Refugees’ health literacy support
18/01/2016

Refugees’ health literacy support

Ben Marais has made a very valid point - having better global access to TB care and prevention is then major means to deal with TB in children.

http://www.aselph.ac.za/index.php/component/content/article?id=114The Albertina Sisulu Executive Leadership Programme in...
09/01/2016

http://www.aselph.ac.za/index.php/component/content/article?id=114
The Albertina Sisulu Executive Leadership Programme in Health (ASELPH) strengthens health transformation in South Africa by building the skills, competencies, and experiences of senior health leaders and managers

Dr. Marcus (Phuti) Molokomme is the CEO of Pelonomi Hospital in Bloemfontein and was previously the CEO of Bongani Regional Hospital. Dr. Molokomme is the co-captain of the first class of ASELPH Fellows at the University of Pretoria. 

Address

BELCHER Road, HEIDEDAL
Bloemfontein

Website

Alerts

Be the first to know and let us send you an email when Pelonomi Hospital Doctors FORUM posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share